| Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity B Meng, A Abdullahi, IATM Ferreira, N Goonawardane, A Saito, I Kimura, ... Nature 603 (7902), 706-714, 2022 | 558 | 2022 |
| Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. T Shirasaka, MF Kavlick, T Ueno, WY Gao, E Kojima, ML Alcaide, ... Proceedings of the National Academy of Sciences 92 (6), 2398-2402, 1995 | 486 | 1995 |
| SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity C Motozono, M Toyoda, J Zahradnik, A Saito, H Nasser, TS Tan, I Ngare, ... Cell host & microbe 29 (7), 1124-1136. e11, 2021 | 364 | 2021 |
| SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity S Ozono, Y Zhang, H Ode, K Sano, TS Tan, K Imai, K Miyoshi, ... Nature communications 12 (1), 848, 2021 | 355 | 2021 |
| M ring, S ring and proximal rod of the flagellar basal body of Salmonella typhimurium are composed of subunits of a single protein, FliF T Ueno, K Oosawa, SI Aizawa Journal of molecular biology 227 (3), 672-677, 1992 | 212 | 1992 |
| Inhibition of human telomerase by rubromycins: implication of spiroketal system of the compounds as an active moiety T Ueno, H Takahashi, M Oda, M Mizunuma, A Yokoyama, Y Goto, ... Biochemistry 39 (20), 5995-6002, 2000 | 185 | 2000 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... Cell 185 (12), 2103-2115. e19, 2022 | 163 | 2022 |
| The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance I Kimura, Y Kosugi, J Wu, J Zahradnik, D Yamasoba, EP Butlertanaka, ... Cell reports 38 (2), 2022 | 162 | 2022 |
| JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1 K Yoshimura, R Kato, K Yusa, MF Kavlick, V Maroun, A Nguyen, T Mimoto, ... Proceedings of the National Academy of Sciences 96 (15), 8675-8680, 1999 | 138 | 1999 |
| Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2′, 3′-Dideoxynucleoside 5′-Triphosphates (∗) T Ueno, T Shirasaka, H Mitsuya Journal of Biological Chemistry 270 (40), 23605-23611, 1995 | 134 | 1995 |
| The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication Y Sobao, H Tomiyama, K Sugi, M Tokunaga, T Ueno, S Saito, S Fujiyama, ... Journal of hepatology 36 (1), 105-115, 2002 | 109 | 2002 |
| Overproduction of the bacterial flagellar switch proteins and their interactions with the MS ring complex in vitro K Oosawa, T Ueno, S Aizawa Journal of bacteriology 176 (12), 3683-3691, 1994 | 106 | 1994 |
| Structure− activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine T Mimoto, R Kato, H Takaku, S Nojima, K Terashima, S Misawa, ... Journal of medicinal chemistry 42 (10), 1789-1802, 1999 | 104 | 1999 |
| SARS-CoV-2 Omicron spike mediated immune escape and tropism shift B Meng, IATM Ferreira, A Abdullahi, N Goonawardane, A Saito, I Kimura, ... BioRxiv, 2021.12. 17.473248, 2021 | 98 | 2021 |
| Attenuation of multiple Nef functions in HIV-1 elite controllers P Mwimanzi, TJ Markle, E Martin, Y Ogata, XT Kuang, M Tokunaga, ... Retrovirology 10, 1-12, 2013 | 94 | 2013 |
| Domain structures of the MS ring component protein (FliF) of the flagellar basal body of Salmonella typhimurium T Ueno, K Oosawa, SI Aizawa Journal of molecular biology 236 (2), 546-555, 1994 | 92 | 1994 |
| Development of fluoroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan M TANAKA, K TAKAHASHI, T SAIKA, I KOBAYASHI, T UENO, ... The Journal of urology 159 (6), 2215-2219, 1998 | 90 | 1998 |
| Comparative Enzymatic Study of HIV-1 Reverse Transcriptase Resistant to 2 ‘, 3 ‘-Dideoxynucleotide Analogs Using the Single-Nucleotide Incorporation Assay T Ueno, H Mitsuya Biochemistry 36 (5), 1092-1099, 1997 | 89 | 1997 |
| Virological characteristics of SARS-CoV-2 BA. 2 variant D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... Biorxiv, 2022.02. 14.480335, 2022 | 88 | 2022 |
| An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity C Motozono, M Toyoda, J Zahradnik, T Ikeda, A Saito, TS Tan, I Ngare, ... BioRxiv, 2021.04. 02.438288, 2021 | 69 | 2021 |
